Saliva Liquid Biopsy (sLB)
David Wong, Director, University of California Los Angeles
Liquid biopsy is a rapidly emerging field to address this unmet clinical
need as diagnostics based on cell-free circulating tumor DNA (ctDNA)
can be a surrogate for the entire tumor genome. The use of ctDNA via
liquid biopsy will facilitate analysis of tumor genomics that is
urgently needed for molecular targeted therapy. Currently, most targeted
approaches are based on PCR and/or next generation sequencing (NGS) for
liquid biopsy applications with performance concordance in the 70-80%
range with biopsy-based genotyping. “Electric Field Induced Release and
Measurement (EFIRM)” is an emerging liquid biopsy technology that
provides the most accurate detection that can assist clinical treatment
decisions for the most common subtype of lung cancer, non-small cell
lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can
extend the disease progress free survival period of these patients.
EFIRM can detection ctDNA at single copy level whereas ddPCR detects
ctDNA a minimum of 10 copy number. In addition EFIRM requires only 40 µl
of sample volume, no sample processing, reaction time is 15min and can
be performed at the point-of-care or high throughput reference lab using
plasma or saliva. In two blinded independent clinical studies, EFIRM
detects actionable EGFR mutations in NSCLC patients with >95%
concordance with biopsy-based genotyping. EFIRM is minimally/
non-invasive detecting the most common EGFR gene mutations that are
treatable with TKI such as Gefitinib or Erlotinib to effectively extend
the progression free survival of lung cancer patients.
|
|